WEBINAR SPONSORED BY:Immune responses are controlled by an exquisite system of stimulatory and inhibitory checkpoints. Cancer cells often find a way to co-opt these
checkpoints to avoid being attacked by the immune system. There is growing interest in blocking inhibitory innate immune checkpoints such as the “don’t
eat me” signal, CD47, which is commonly overexpressed on cancer cells, and the TAM receptor family of tyrosine kinases. Also, small molecule agonists
against STING—a protein that ramps up production of interferons and cytokines—are major targets on the radar for therapeutic development, as well as
molecules that target Toll-like Receptors (TLRs) and RIG-I-like Receptors (RLRs). Join us for a discussion about first-in-class STING agonists and innate
immune checkpoints in cancer.
ANDREA VAN ELSAS,PhD
Chief Scientific Officer
Aduro Biotech, Inc.Keeping Cancer in Check:
Innate Immunity and Checkpoint Inhibitors
COMINGSOON
TUESDAY, MARCH 26
2:30-4:00 EASTERN TIMEREGISTER NOW!
http://www.the-scientist.com/cancerincheck
The webinar video will also be available at this link.JEREMY R. GRAFF,PhD
President and Chief Scientific Officer
Biothera PharmaceuticalsTIMO VAN DEN BERG,PhD
Professor (Immunotherapy), Dept. of Molecular Cell
Biology and Immunology
VU Medical Center
Head, Dept. of Blood Cell Research, Sanquin Research
Academic Medical Center, AmsterdamTOPICS TO BE COVERED:
•Immune-oncology beyond PD1: preclinical and first
clinical data using ADU-S100, a first-in-class STING
agonist
•Mechanism of an immune-modulating biologic for
late-stage cancer- The CD47-SIRPα innate immune checkpoint in cancer
ONDEMAND
In recent years, an avalanche of new compounds has been developed to treat cancer with immunotherapy. However, novel biomarkers are required to
guide these treatments. The complexity of cancer and the immune response mean predictive biomarkers for immuno-oncology can differ vastly between
people and cancer subtypes. New approaches for biomarker discovery include using next-generation gene expression profiling, which allows patient-level
biomarker determination, as well as multiplex spatial protein profiling to identify protein targets, including immune cell markers and checkpoint proteins.
To delve deeper into this issue, The Scientist brings together a panel of experts to discuss their research and provide insight into how biomarker bottlenecks
are being overcome.
The Biomarker Bottleneck in Immuno-Oncology:
Understanding to OvercomeWATCH NOW!
http://www.the-scientist.com/biomarkerbottleneck-webinarTOPICS TO BE COVERED:- Assessing heterogeneity of immune cell infiltration in
tumors to predict response to cancer immunotherapy - Mapping the landscape of tumors
WEBINAR SPONSORED BY:ALICE O. KAMPHORST,PhD
Assistant Professor
Department of Oncological Sciences
Precision Immunology Institute
Icahn School of Medicine at Mount SinaiEVISA GJINI,PhD
Associate Director
Department of Pathology
Brigham and Women’s Hospital
Dana Farber Cancer Institute